P Kerbrat

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  2. ncbi [On the subject of the recommendations for clinical practice: 2003 Standards, Options and Recommendations for the medical frontline treatment of patients with malignant epithelial ovarian tumors. Update (summary version)]
    P Kerbrat
    Departement d Oncologie Medicale, Centre Eugene Marquis, Rennes, France
    Gynecol Obstet Fertil 32:669. 2004
  3. ncbi [On the subject of the recommendations for clinical practice: 2003 Standards, Options and Recommendations for the medical frontline treatment of patients with malignant epithelial ovarian tumors. Update (summary version)]
    P Kerbrat
    Departement d Oncologie Medicale, Centre Eugene Marquis, Rennes, France
    Gynecol Obstet Fertil 32:992. 2004
  4. pmc Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
    P Kerbrat
    Department of Medical Oncology, Centre Eugene Marquis, Universite de Rennes, rue de la Bataille Flandres Dunkerque, CS 44229, 35042 Rennes, France
    Br J Cancer 96:1633-8. 2007
  5. ncbi Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer
    P Kerbrat
    Centre Eugene Marquis, France
    Eur J Cancer 39:317-20. 2003
  6. doi A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Cedex, France
    Ann Oncol 24:1099-104. 2013
  7. ncbi Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1985-9. 2007
  8. ncbi Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
    S Culine
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 18:917-24. 2007
  9. ncbi Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
    J C Eymard
    Institut Jean Godinot, Reims, France
    Ann Oncol 18:1064-70. 2007
  10. ncbi Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results
    P Fumoleau
    Centre Georges Francois Leclerc, Dijon, France
    Ann Oncol 17:85-92. 2006

Detail Information

Publications30

  1. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  2. ncbi [On the subject of the recommendations for clinical practice: 2003 Standards, Options and Recommendations for the medical frontline treatment of patients with malignant epithelial ovarian tumors. Update (summary version)]
    P Kerbrat
    Departement d Oncologie Medicale, Centre Eugene Marquis, Rennes, France
    Gynecol Obstet Fertil 32:669. 2004
  3. ncbi [On the subject of the recommendations for clinical practice: 2003 Standards, Options and Recommendations for the medical frontline treatment of patients with malignant epithelial ovarian tumors. Update (summary version)]
    P Kerbrat
    Departement d Oncologie Medicale, Centre Eugene Marquis, Rennes, France
    Gynecol Obstet Fertil 32:992. 2004
  4. pmc Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
    P Kerbrat
    Department of Medical Oncology, Centre Eugene Marquis, Universite de Rennes, rue de la Bataille Flandres Dunkerque, CS 44229, 35042 Rennes, France
    Br J Cancer 96:1633-8. 2007
    ..Epi-Vnr regimen provided a good efficacy in such poor-prognosis breast cancer patients, and could be an alternative to FEC100, taking into account respective safety profiles of both regimens...
  5. ncbi Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer
    P Kerbrat
    Centre Eugene Marquis, France
    Eur J Cancer 39:317-20. 2003
    ..There were no objective responses, 7 patients had stable disease. These results do not support the further evaluation of LU 103793 in metastatic breast cancer patients using this dose and schedule...
  6. doi A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, Cedex, France
    Ann Oncol 24:1099-104. 2013
    ..SARCGYN phase III study compared adjuvant polychemotherapy followed by pelvic radiotherapy (RT) (arm A) versus RT alone (arm B) conducted to detect an increase ≥ 20% of 3-year PFS...
  7. ncbi Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 18:1985-9. 2007
    ..The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO)...
  8. ncbi Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
    S Culine
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 18:917-24. 2007
    ..High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin...
  9. ncbi Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer
    J C Eymard
    Institut Jean Godinot, Reims, France
    Ann Oncol 18:1064-70. 2007
    ..We assessed the activity and safety of docetaxel alone and docetaxel-estramustine in HRPC...
  10. ncbi Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results
    P Fumoleau
    Centre Georges Francois Leclerc, Dijon, France
    Ann Oncol 17:85-92. 2006
    ..The aim of the study was to evaluate and compare incidence and risk factors of left ventricular dysfunction (LVD) in early breast cancer patients receiving (E+) or not (E-) epirubicin-based adjuvant chemotherapy...
  11. ncbi Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
    M Campone
    Ann Oncol 16:1343-51. 2005
    ..The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients...
  12. ncbi Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial
    H Roche
    Institut Claudius Regaud, Toulouse, France
    Ann Oncol 17:1221-7. 2006
    ..The purpose of this study was to determine optimal adjuvant therapy between complete hormonal blockade in premenopausal patients with hormone receptor positive breast cancer and one to three positive nodes...
  13. ncbi Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer
    R Deporte-Fety
    Centre Rene Gauducheau, Nantes, France
    Cancer Chemother Pharmacol 53:233-8. 2004
    ..To develop a population pharmacokinetic model of vinorelbine administered by short intravenous infusion in metastatic breast cancer patients...
  14. ncbi Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axil
    P Fumoleau
    Department of Medical Oncology, Centre Rene Gauducheau, Centre Regional de Lutte Contre le Cancer Nantes Atlantique, Nantes
    J Clin Oncol 19:612-20. 2001
    ..To determine whether intensifying the dose of adjuvant chemotherapy improves the outcome of women with primary breast cancer and 10 or more involved axillary nodes...
  15. ncbi UFT/leucovorin plus vinorelbine combination for advanced breast cancer
    P Fumoleau
    Medical Oncology Department, Centre Rene Gauducheau, Nantes, France
    Oncology (Williston Park) 14:50-5. 2000
    ..No pharmacokinetic interaction between UFT and vinorelbine was observed...
  16. ncbi Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone
    P Pautier
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif Cedex, France
    Int J Gynecol Cancer 14:1112-7. 2004
    ..Compared to a case-control study of adjuvant radiotherapy alone, results were not decreased by the addition of a toxic chemotherapy...
  17. ncbi Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer
    S Urien
    Centre Rene Huguenin, Saint Cloud, France
    Cancer Chemother Pharmacol 52:99-107. 2003
    ..The pharmacokinetics of ftorafur, 5-fluorouracil (5FU) and uracil were investigated in order to built a population pharmacokinetic model for the anticancer drug UFT, administered with leucovorin and vinorelbine...
  18. ncbi Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors
    P Pautier
    Departments of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Int J Gynecol Cancer 18:446-52. 2008
    ..Five patients experienced a low bleomycin pulmonary toxicity. BEP regimen appears to be an active regimen for OGCT in first-line chemotherapy...
  19. doi Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor
    T de La Motte Rouge
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif
    Ann Oncol 19:1435-41. 2008
    ..Current treatment consists of surgery followed by bleomycin, etoposide, and cisplatin (BEP) chemotherapy. However, given the rarity of this tumor, ovarian YST-specific survival and outcome after such treatment are not precisely known...
  20. doi A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors
    C Theodore
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ann Oncol 19:1465-9. 2008
    ..The aim of this study is to determine feasibility and efficacy of the combination regimen oxaliplatin and paclitaxel in patients with cisplatin (CDDP)-refractory germ-cell tumors (GCT)...
  21. ncbi Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study
    P Viens
    Institut Paoli-Calmettes, Marseille, France
    Am J Clin Oncol 24:328-35. 2001
    ..1 months and median overall survival was 22.7 months. On the basis of efficacy and toxicity, the recommended dose of the combination is epirubicin 100 mg/m(2) plus docetaxel 75 mg/m(2)...
  22. ncbi Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
    H C Wagenaar
    Department of Gynecology, Leiden University Medical Center, The Netherlands
    Eur J Gynaecol Oncol 22:187-93. 2001
    ..CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable...
  23. ncbi Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients
    V Dieras
    Institut Curie, Paris, France
    Ann Oncol 13:258-66. 2002
    ..This multicentre phase II open-label study evaluated safety and antitumour activity of oxaliplatin in cisplatin or carboplatin (cis/carboplatin) +/- taxane-pretreated advanced ovarian cancer (AOC) patients...
  24. ncbi Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02
    M Namer
    Centre Antoine Lacassagne, Nice, France
    Ann Oncol 17:65-73. 2006
    ....
  25. ncbi Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group
    M S Aapro
    Division d Oncologie, Hopital Cantonal Universitaire, Geneve, Switzerland
    Ann Oncol 14:441-8. 2003
    ....
  26. ncbi Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
    J Baselga
    Vall d Hebron University Hospital, Barcelona, Spian
    Ann Oncol 14:1383-90. 2003
    ..The primary end point was to choose the best of two doses of arzoxifene based on the response rate or the clinical benefit rate (CBR). Pharmacokinetics and toxicities were also assessed...
  27. ncbi [Extraosseous Ewing's sarcoma of the spinal epidural space]
    X Morandi
    Service de Neurochirurgie, CHRU Pontchaillou, Rennes Cedex 2
    Neurochirurgie 47:38-44. 2001
    ..Twelve patients died, 1 to 54 months (mean, 18) after diagnosis. Even though the number of patients was too small in this series for statistical analysis, partially resected tumors do appear to be associated with a higher mortality...
  28. ncbi [Patient information booklet SOR SAVOIR PATIENT: understanding ovarian cancer, a guide for cancer patients and family members]
    H Hoarau
    FNCLCC, Paris, France
    Gynecol Obstet Fertil 34:1195-204. 2006
  29. ncbi Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases
    B Cutuli
    Department of Radiotherapy, Centre Paul Strauss, , 67085 Cedex, Strasbourg, France
    Radiother Oncol 59:247-55. 2001
    ..This screening seems of importance due to excellent prognosis in our T(1S)T(1) groups, and the possibility of offering these young women a conservative treatment...